Biofil Chemicals & Pharmaceuticals balance sheet

As of Mar 2026

Total assets: ₹42.8cr−15.9% on Mar 2025
Shareholders' equity: ₹21.6cr+14.8% on Mar 2025
Total debt: ₹3.0cr+540.8% on Mar 2025
Cash and investments: ₹0.1cr−51.8% on Mar 2025

₹ crore except per share

Tap a line for its trend	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Current assets
Non-current assets					FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	6.9	8.3	8.6	9.0
	0.1	0.1	0.1	—
	7.0	8.4	8.7	9.0
	4.0	3.3	2.5	1.2
	27.6	38.3	33.0	20.5
	0.1	0.1	0.1	0.0
	3.3	0.1	2.2	0.0
	—	0.6	—	—
	30.9	39.2	35.3	20.5
	1.0	—	0.5	0.7
	35.9	42.6	38.4	22.4
	42.8	51.0	47.1	31.4
Equity
	16.3	16.3	16.3	16.3
	5.3	2.5	1.9	1.0
	21.6	18.8	18.2	17.3
	21.6	18.8	18.2	17.3
Liabilities
	0.6	0.3	0.4	0.4
	0.6	0.3	0.4	0.4
	3.0	0.5	0.4	0.5
	17.1	31.0	27.6	12.6
	20.1	31.5	28.0	13.2
	0.4	0.2	0.2	0.2
	0.2	0.2	0.3	0.3
	20.7	31.8	28.5	13.7
	21.3	32.2	28.9	14.1
	42.8	51.0	47.1	31.4
Trade payables — MSME split
	17.1	31.0	—	—

Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

alphave

BIOFILCHEM₹29.26

Biofil Chemicals & Pharmaceuticals Limited

· Pharma & Health

₹ CrorePeersMANGALAM VINEETLAB LASA ORTINGLOBE KREBSBIO ALPA BALPHARMA NATCAPSUQMcap ₹47.6 Cr

View

In ₹ Crore except Per Share As of	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	9.0	8.6	8.3	6.9	6.9
+ Other Non-current Assets	—	0.1	0.1	0.1	0.1
Total Non-current Assets	9.0	8.7	8.4	7.0	7.0
Current Assets
+ Inventories	1.2	2.5	3.3	4.0	4.0
+ Trade Receivables	20.5	33.0	38.3	27.6	27.6
+ Cash & Cash Equivalents	0.0	0.1	0.1	0.1	0.1
+ Other Bank Balances	0.0	2.2	0.1	3.3	3.3
+ Other Current Financial Assets	—	—	0.6	—	—
Current Financial Assets	20.5	35.3	39.2	30.9	30.9
+ Other Current Assets	0.7	0.5	—	1.0	1.0
Total Current Assets	22.4	38.4	42.6	35.9	35.9
Total Assets	31.4	47.1	51.0	42.8	42.8
Equity
+ Equity Share Capital	16.3	16.3	16.3	16.3	16.3
+ Other Equity / Reserves	1.0	1.9	2.5	5.3	5.3
Equity — Owners of Parent	17.3	18.2	18.8	21.6	21.6
Total Equity	17.3	18.2	18.8	21.6	21.6
Liabilities
+ Deferred Tax Liabilities	0.4	0.4	0.3	0.6	0.6
Non-current Liabilities	0.4	0.4	0.3	0.6	0.6
+ Borrowings — Current	0.5	0.4	0.5	3.0	3.0
+ Trade Payables	12.6	27.6	31.0	17.1	17.1
Current Financial Liabilities	13.2	28.0	31.5	20.1	20.1
+ Provisions — Current	0.2	0.2	0.2	0.4	0.4
+ Other Current Liabilities	0.3	0.3	0.2	0.2	0.2
Current Liabilities	13.7	28.5	31.8	20.7	20.7
Total Liabilities	14.1	28.9	32.2	21.3	21.3
Total Equity & Liabilities	31.4	47.1	51.0	42.8	42.8
Trade Payables — MSME split
+ Dues to Other Creditors — Current	—	—	31.0	17.1	17.1

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.